Publications by authors named "Maura Lash"
Article Synopsis
- A study focused on 13 patients with advanced HIV (CD4 count under 200 cells/μL) who also had severe mpox and multiple organ issues.* -
- These patients underwent long treatments with various medications, including tecovirimat and others, but still faced serious health complications.* -
- The outcomes showed that they had long hospital stays and a high death rate, highlighting the severity of their conditions.*
We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat. Treatment rates by race/ethnicity were 38.
View Article and Find Full Text PDFMonkeypox (mpox) cases in the 2022 outbreak have primarily occurred among adult gay, bisexual, and other men who have sex with men (MSM); however, other populations have also been affected (1). To date, data on mpox in cisgender women and pregnant persons have been limited. Understanding transmission in these populations is critical for mpox prevention.
View Article and Find Full Text PDFArticle Synopsis
- * Among 6,799 live-born infants studied from December 2015 to March 2018, 4.6% had Zika-related birth defects, with a higher rate of 6.1% in those with confirmed infection.
- * Common defects included microcephaly and other brain abnormalities, with many infants showing multiple defects, highlighting the need for targeted surveillance during potential Zika outbreaks.
Article Synopsis
- The study analyzed 112 deaths attributed to SARS-CoV-2 among individuals under 21 in the U.S. between February and July 2020, highlighting demographic and clinical characteristics.* -
- Most decedents were male (63%), with a median age of 17, and a significant number identified as Black (28%) or Hispanic (46%); many had underlying health conditions like obesity and asthma.* -
- Children who died from COVID-19 were more likely to have pre-existing health issues compared to those who met criteria for multisystem inflammatory syndrome (MIS-C), which affected 14% of the decedents.*
Background: Multisystem inflammatory syndrome in children (MIS-C), temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been identified in infants <12 months old. Clinical characteristics and follow-up data of MIS-C in infants have not been well described. We sought to describe the clinical course, laboratory findings, therapeutics and outcomes among infants diagnosed with MIS-C.
View Article and Find Full Text PDFColonization After Discharge to a Community Setting: New York City, 2017-2019.
Open Forum Infect Dis
January 2021
Background: Patients colonized with multidrug-resistant and discharged to a community setting can subsequently seek care in a different healthcare facility and might be a source of nosocomial transmission of .
Methods: We designed a case management pilot program for a cohort of New York City residents who had a history of positive culture identified during clinical or screening activities in healthcare settings and discharged to a community setting during 2017-2019. Approximately every 3 months, case managers coordinated colonization assessments, which included swabs of groin, axilla, and body sites yielding previously.
During the course of the coronavirus disease 2019 (COVID-19) pandemic, reports of a new multisystem inflammatory syndrome in children (MIS-C) have been increasing in Europe and the United States (1-3). Clinical features in children have varied but predominantly include shock, cardiac dysfunction, abdominal pain, and elevated inflammatory markers, including C-reactive protein (CRP), ferritin, D-dimer, and interleukin-6 (1). Since June 2020, several case reports have described a similar syndrome in adults; this review describes in detail nine patients reported to CDC, seven from published case reports, and summarizes the findings in 11 patients described in three case series in peer-reviewed journals (4-6).
View Article and Find Full Text PDFArticle Synopsis
- Since February 2020, the U.S. has reported about 6.5 million COVID-19 cases and approximately 190,000 deaths, with a focus on individuals under 21 years old.
- Among the 121 deaths in this age group during the early pandemic, 63% were males, and most were aged between 10-20 years, with a significant percentage being Hispanic and Black.
- About 75% of those who died had underlying medical conditions, highlighting the need for ongoing monitoring and effective prevention strategies as schools reopen.
In April 2020, during the peak of the coronavirus disease 2019 (COVID-19) pandemic in Europe, a cluster of children with hyperinflammatory shock with features similar to Kawasaki disease and toxic shock syndrome was reported in England* (1). The patients' signs and symptoms were temporally associated with COVID-19 but presumed to have developed 2-4 weeks after acute COVID-19; all children had serologic evidence of infection with SARS-CoV-2, the virus that causes COVID-19 (1). The clinical signs and symptoms present in this first cluster included fever, rash, conjunctivitis, peripheral edema, gastrointestinal symptoms, shock, and elevated markers of inflammation and cardiac damage (1).
View Article and Find Full Text PDFObjective: To evaluate whether antenatal Zika virus infection is associated with risk of having a small-for-gestational-age (SGA) neonate, risk of preterm birth, and lower mean birth weight of term neonates.
Methods: For this retrospective observational study, we linked birth record data for women who delivered liveborn singleton neonates in New York City in 2016 to data for pregnant women with Zika virus infection reported to the New York City Health Department. We restricted the analysis to nonsmoking, nonwhite women and adjusted for maternal characteristics.
Background: Our goal was to characterize the epidemiology and clinical significance of congenital Zika virus (ZIKV) exposure by prospectively following a cohort of infants with possible congenital exposure through their first year of life.
Methods: We included infants born in New York City between 2016 and 2017 who had or were born to a woman who had laboratory evidence of ZIKV infection during pregnancy. We conducted provider/patient interviews and reviewed medical records to collect information about the pregnant women and, for infants, clinical and neurodevelopmental status at birth and 2, 6, and 12 months of age.